Sign up to save your podcasts
Or
Share A new era in type 1 diabetes treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A new era in type 1 diabetes treatment
Could insulin dependency be a burden of the past for patients with type 1 diabetes? Matthias von Herrath, M.D., scientific director of the Diabetes Research Institute, is hopeful. Dr. von Herrath joined Inside U Miami Medicine to share how he and his teams are working on the
ultimate T1D moonshot: To restore or preserve natural insulin production and normalize blood sugar levels without imposing other risks that accompany immune suppression.
In episode one of this two-part conversation, Dr. von Herrath reviews the current understandings of the pathogenesis of T1D and describes the mechanisms of the first FDA-approved treatment for delaying T1D for those at risk: Tzield (teplizumab-mzwv), an anti-CD3 monoclonal antibody.
View all episodes
By University of Miami Miller School of MedicineCould insulin dependency be a burden of the past for patients with type 1 diabetes? Matthias von Herrath, M.D., scientific director of the Diabetes Research Institute, is hopeful. Dr. von Herrath joined Inside U Miami Medicine to share how he and his teams are working on the
ultimate T1D moonshot: To restore or preserve natural insulin production and normalize blood sugar levels without imposing other risks that accompany immune suppression.
In episode one of this two-part conversation, Dr. von Herrath reviews the current understandings of the pathogenesis of T1D and describes the mechanisms of the first FDA-approved treatment for delaying T1D for those at risk: Tzield (teplizumab-mzwv), an anti-CD3 monoclonal antibody.